Skip to main content

Table 2 Summary of plasma metformin, remogliflozin etabonate, remogliflozin, and GSK279782 PK parameters

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Metformin PK parameter MET BID MET + RE BID
N = 13 N = 13
AUC(0–12) (h.ng/mL) 7141.3 (24) 7520.8 (27)
Cmax (ng/mL) 1018.2 (26) 1025.3 (25)
tmax (h) 4.0 (1.0 - 6.0) 4.0 (1.0–6.0)
Remogliflozin etabonate (prodrug) PK Parameter RE BID MET + RE BID
N = 12-13 a N = 12-13 a
AUC(0–last) (h.ng/mL) 98.9 (69) 102.1 (49)
Cmax (ng/mL) 79.5 (107) 67.7 (77)
tmax (h) 3.0 (1.0–4.0) 3.0 (1.0–6.0)
Remogliflozin (active entity) PK Parameter RE BID MET + RE BID
N = 13 N = 13
AUC(0–12) (h.ng/mL) 6814.3 (33) 6425.9 (33)
Cmax (ng/mL) 2688.6 (52) 2124.6 (63)
tmax (h) 3.0 (1.0–4.0) 3.0 (1.0 - 6.0)
GSK279782 (active metabolite) PK Parameter RE BID MET + RE BID
N = 13 N = 13
AUC(0–12) (h.ng/mL) 1527.9 (37) 1472.9 (36)
Cmax (ng/mL) 462.8 (39) 361.9 (38)
tmax (h) 4.0 (1.0–4.0) 4.0 (1.0–8.0)
  1. Values are geometric mean (%CVb) for each parameter, except for tmax which is median (range). PK, pharmacokinetic; MET BID, metformin 500 mg every 12 hours; MET + RE BID, metformin 500 mg + remogliflozin etabonate 500 mg every 12 hours; RE BID, remogliflozin etabonate 500 mg every 12 hours.
  2. a AUC not evaluable for one subject.